GERN Quote, Financials, Valuation and Earnings

Jaguar Health, Inc. has a net margin of -39.02% compared to Geron Corp.'s net margin of -312.94%. Geron Corp.'s return on equity of -29.65% beat Jaguar Health, Inc.'s return on equity of -524.57%.

Geron Corp. has a consensus price target of $3.60, signalling upside risk potential of 122.22%. On the other hand Jaguar Health, Inc. has an analysts' consensus of $25.50 which suggests that it could grow by 3705.97%. Given that Jaguar Health, Inc. has higher upside potential than Geron Corp., analysts believe Jaguar Health, Inc. is more attractive than Geron Corp..

Geron Corp. has a beta of 0.620, which suggesting that the stock is 38.038% less volatile than S&P 500. In comparison Jaguar Health, Inc. has a beta of 0.092, suggesting its less volatile than the S&P 500 by 90.778%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jaguar Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. Jaguar Health, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $47.2M, which are larger than Jaguar Health, Inc. quarterly revenues of $3.1M. Geron Corp.'s net income of -$18.4M is lower than Jaguar Health, Inc.'s net income of -$9.6M. Notably, Geron Corp.'s price-to-earnings ratio is -- while Jaguar Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 5.55x versus 0.23x for Jaguar Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -39.02% compared to Geron Corp.'s net margin of -316.61%. Geron Corp.'s return on equity of -29.65% beat Plus Therapeutics, Inc.'s return on equity of --.

Geron Corp. has a consensus price target of $3.60, signalling upside risk potential of 122.22%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 2016.2%. Given that Plus Therapeutics, Inc. has higher upside potential than Geron Corp., analysts believe Plus Therapeutics, Inc. is more attractive than Geron Corp..

Geron Corp. has a beta of 0.620, which suggesting that the stock is 38.038% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $47.2M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Geron Corp.'s net income of -$18.4M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Geron Corp.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 5.55x versus 4.17x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rezolute, Inc. has a net margin of -39.02% compared to Geron Corp.'s net margin of --. Geron Corp.'s return on equity of -29.65% beat Rezolute, Inc.'s return on equity of -63.8%.

Geron Corp. has a consensus price target of $3.60, signalling upside risk potential of 122.22%. On the other hand Rezolute, Inc. has an analysts' consensus of $4.25 which suggests that it could grow by 36.22%. Given that Geron Corp. has higher upside potential than Rezolute, Inc., analysts believe Geron Corp. is more attractive than Rezolute, Inc..

Geron Corp. has a beta of 0.620, which suggesting that the stock is 38.038% less volatile than S&P 500. In comparison Rezolute, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.658%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rezolute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. Rezolute, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $47.2M, which are larger than Rezolute, Inc. quarterly revenues of --. Geron Corp.'s net income of -$18.4M is lower than Rezolute, Inc.'s net income of -$18.2M. Notably, Geron Corp.'s price-to-earnings ratio is -- while Rezolute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 5.55x versus -- for Rezolute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

SELLAS Life Sciences Group, Inc. has a net margin of -39.02% compared to Geron Corp.'s net margin of --. Geron Corp.'s return on equity of -29.65% beat SELLAS Life Sciences Group, Inc.'s return on equity of -103.86%.

Geron Corp. has a consensus price target of $3.60, signalling upside risk potential of 122.22%. On the other hand SELLAS Life Sciences Group, Inc. has an analysts' consensus of $6.83 which suggests that it could grow by 83.2%. Given that Geron Corp. has higher upside potential than SELLAS Life Sciences Group, Inc., analysts believe Geron Corp. is more attractive than SELLAS Life Sciences Group, Inc..

Geron Corp. has a beta of 0.620, which suggesting that the stock is 38.038% less volatile than S&P 500. In comparison SELLAS Life Sciences Group, Inc. has a beta of 2.273, suggesting its more volatile than the S&P 500 by 127.327%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SELLAS Life Sciences Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. SELLAS Life Sciences Group, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $47.2M, which are larger than SELLAS Life Sciences Group, Inc. quarterly revenues of --. Geron Corp.'s net income of -$18.4M is lower than SELLAS Life Sciences Group, Inc.'s net income of -$6.8M. Notably, Geron Corp.'s price-to-earnings ratio is -- while SELLAS Life Sciences Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 5.55x versus -- for SELLAS Life Sciences Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.